Amid mounting pressure from generics and private-label products, branded drug manufactures are counting on Rx-to-OTC switches to drive growth and keep revenues flowing. Recent switches have generated $1 billion—about 10% of total industry sales for 2009—making this an attractive path for drug makers. With a number of potentially huge switches on the horizon, the next few years could see a flurry of activity that will drive post-recessionary growth through 2014. read more…
